Showing session: reset
Immunotherapy Combinations: The New Frontier in Lung Cancer
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Chairperson
Alice T Shaw
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
Leena Gandhi
NYU Langone Health, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Roy S Herbst
Yale Cancer Ctr., New Haven, CT, United States
- Free
- slides video
- audio + slides
- All slides included
IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
Mark A Socinski
Florida Hospital Cancer Institute, Orlando, FL, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Justin F. Gainor
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
Matthew D. Hellmann
Memorial Sloan Kettering Cancer Center Hospital, New York, NY, United States
- Free
- podium video
- audio + slides
- Some slides withheld
Discussant
Naiyer Rizvi
Columbia Univ., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Suresh S. Ramalingam
Winship Cancer Institute, Emory University, Atlanta, GA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
David L. Rimm
Yale Univ. School of Medicine, New Haven, CT, United States
- Free
- slides video
- audio + slides
- All slides included
Neoadjuvant PD-1 blockade in resectable lung cancer
Drew M Pardoll
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
John Heymach
UT MD Anderson Cancer Ctr., Houston, TX, United States